Effectiveness and safety of telitacicept for refractory generalized myasthenia gravis: a retrospective study

医学 重症肌无力 耐火材料(行星科学) 强的松 不利影响 回顾性队列研究 剂量 内科学 天体生物学 物理
作者
Jing Lin,Yue Li,Mengcui Gui,Bitao Bu,Zhijun Li
出处
期刊:Therapeutic Advances in Neurological Disorders [SAGE Publishing]
卷期号:17: 17562864241251476-17562864241251476 被引量:28
标识
DOI:10.1177/17562864241251476
摘要

Background: Refractory generalized myasthenia gravis (GMG) remains a substantial therapeutic challenge. Telitacicept, a recombinant human B-lymphocyte stimulator receptor-antibody fusion protein, holds promise for interrupting the immunopathology of this condition. Objectives: This study retrospectively assessed the effectiveness and safety of telitacicept in patients with refractory GMG. Design: A single-center retrospective study. Methods: Patients with refractory GMG receiving telitacicept (160 mg/week or biweekly) from January to September in 2023 were included. We assessed effectiveness using Myasthenia Gravis Foundation of America post-intervention status (MGFA-PIS), myasthenia gravis treatment status and intensity (MGSTI), quantitative myasthenia gravis (QMG), and MG-activity of daily living (ADL) scores, alongside reductions in prednisone dosage at 3- and 6-month intervals. Safety profiles were also evaluated. Results: Sixteen patients with MGFA class II–V refractory GMG were included, with eight females and eight males. All patients were followed up for at least 3 months, and 11 patients reached 6 months follow-up. At the 3-month evaluation, 75% (12/16) demonstrated clinical improvement with MGFA-PIS. One patient achieved pharmacological remission, two attained minimal manifestation status, and nine showed functional improvement; three remained unchanged, and one deteriorated. By the 6-month visit, 90.1% (10/11) sustained significant symptomatic improvement. MGSTI scores and prednisone dosages significantly reduced at both follow-ups ( p < 0.05). MG-ADL and QMG scores showed marked improvement at 6 months ( p < 0.05). The treatment was well tolerated, with no severe adverse events such as allergy or infection reported. Conclusion: Our exploratory investigation suggests that telitacicept is a feasible and well-tolerated add-on therapy for refractory GMG, offering valuable clinical evidence for this novel treatment option.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
逆流的鱼完成签到,获得积分10
1秒前
852的应助被tang采纳,获得10
1秒前
2秒前
molihuakai的应助被Benthesikyme采纳,获得10
2秒前
1st发布了新的文献求助10
2秒前
深情安青的应助被科研通管家采纳,获得10
3秒前
3秒前
Nicu发布了新的文献求助10
3秒前
Jun的应助被科研通管家采纳,获得20
3秒前
上官若男的应助被科研通管家采纳,获得10
3秒前
4秒前
CarryLJR的应助被湖工大保卫处采纳,获得10
4秒前
爆米花的应助被科研通管家采纳,获得10
4秒前
4秒前
小萌兽发布了新的文献求助50
4秒前
Orange的应助被科研通管家采纳,获得10
4秒前
ding的应助被科研通管家采纳,获得10
4秒前
syvshc的应助被nikola采纳,获得10
4秒前
CodeCraft的应助被科研通管家采纳,获得10
4秒前
4秒前
华仔的应助被科研通管家采纳,获得10
4秒前
小二郎的应助被科研通管家采纳,获得10
5秒前
Jasper的应助被科研通管家采纳,获得10
5秒前
科研通AI6.3的应助被Bai采纳,获得10
5秒前
丘比特的应助被科研通管家采纳,获得10
5秒前
情怀的应助被科研通管家采纳,获得10
5秒前
wanci的应助被科研通管家采纳,获得10
5秒前
852的应助被1111采纳,获得10
5秒前
pykw的应助被科研通管家采纳,获得10
5秒前
爆米花的应助被科研通管家采纳,获得10
5秒前
5秒前
cheesy的应助被科研通管家采纳,获得10
5秒前
DW的应助被科研通管家采纳,获得10
6秒前
6秒前
思源的应助被科研通管家采纳,获得10
6秒前
Owen的应助被科研通管家采纳,获得10
6秒前
n01W97给听雨的求助进行了留言
7秒前
马颗粒发布了新的文献求助10
7秒前
7秒前
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8178807
求助须知:如何正确求助?哪些是违规求助? 9569558
关于积分的说明 21805222
捐赠科研通 7773974
什么是DOI,文献DOI怎么找? 3432933
关于科研通互助平台的介绍 2556873
邀请新用户注册赠送积分活动 2478593